Orlistat is an FDA-approved drug for long-term treatment of obesity. It works by blocking the absorption of dietary fat. When taken with meals, it reduces the risk of obesity-related conditions like type 2 diabetes, hypertension, and dyslipidemia. Orlistat leads to greater weight loss than placebo when used along with lifestyle changes like diet and exercise. It also helps maintain weight loss and lessens weight regain over two years.

1. “Quick Aid to Shed
Extra Weight”
SLIMAGE

2. SLIMAGEOrlistat 120mg Capsule
SLIMAGE

3. Only antiobesity drug approved
by FDA for long term use;
BMI > 27kg/m2
SLIMAGE

4. From: Long-term Drug Treatment for Obesity: A Systematic and Clinical Review
JAMA. 2014;311(1):74-86.
doi:10.1001/jama.2013.281361
Drugs With US Food and Drug Administration–Approved Indication for Obesity
Table Title:
SLIMAGE

5. FDA Approves Orlistat, an antiobesity formula

6. Reduces the risk of;
Type II Diabetes
Hypertension
Dyslipidemia
SLIMAGE
Diabetes Care June 2002 Vol. 25 no. 6 1033-1041

7. Blocks GI lipase enzyme’s activity.
Unable to break triglycerides down
into component parts.
Dietary fat remains undigested &
unabsorbed.
SLIMAGE

8. Minimal systemic absorption
Safe & well tolerated
No bothersome side effects
SLIMAGE

9. Obesity management including;
Weight loss, weight maintenance
(In conjunction with a reduced calorie diet)
Risk reduction for weight regain after prior weight
loss.
Obese patients with presence of risk factors i.e.
Hypertension, Diabetes & Dyslipidemia.
SLIMAGE

10. One capsule 3 times daily with
each main meal, during or up
to 1 hour after meal
SLIMAGE

11. Dose should be omitted if a meal
is missed or contains no fat
SLIMAGE

12. Contraindicated in;
Pregnancy
Chronic metabolic syndrome
Cholestasis
Hypersensitivity to the drug
SLIMAGE

13. From: The Effect of Orlistat-Induced Weight Loss, Without Concomitant Hypocaloric Diet,
on Cardiovascular Risk Factors and Insulin Sensitivity in Young Obese Chinese Subjects
With or Without Type 2 Diabetes Arch Intern Med. 2002;162(21):2428-2435.
doi:10.1001/archinte.162.21.2428
Changes in body weight and waist circumference in 33 obese patients with type 2
diabetes and 27 nondiabetic obese patients during a 6-month treatment with orlistat,
120 mg 3 times daily. A, Change during the study in body weight; B, percentage of
changes in body weight; C, change in waist circumference; and D, percentage of
changes in waist circumference. Changes are measured from the initial baseline
values. Data are given as mean ± SEM.
SLIMAGE

14. Two-year treatment with orlistat plus
diet significantly promotes weight
loss, lessens weight regain, and
improves some obesity-related
disease risk factors.
JAMA. 1999 Jan 20;281(3):235-42.
SLIMAGE

15. Short-term orlistat treatment
without the use of a hypocaloric diet
significantly improved insulin
sensitivity and cardiovascular risk
profiles in severely obese Chinese
patients with or without type 2
diabetes.
Arch Intern Med. 2002;162(21):2428-2435.
doi:10.1001/archinte.162.21.2428.
SLIMAGE

16. Medications approved for long-term
obesity treatment, when used as an
adjunct to lifestyle intervention, lead
to greater mean weight loss and an
increased likelihood of achieving
clinically meaningful 1-year weight
loss relative to placebo.
JAMA. 2014;311(1):74-86. doi:10.1001/jama.2013.281361.
SLIMAGE

17. The addition of orlistat to a
conventional weight loss regimen
significantly improved oral glucose
tolerance and diminished the rate of
progression to the development of
impaired glucose tolerance and type
2 diabetes.
Arch Intern Med. 2000;160(9):1321-1326.
doi:10.1001/archinte.160.9.1321.
SLIMAGE

18. Proud to be
associated with
today’s CME
Program
SLIMAGE

19. Phr. Asad Kamran
Technical Consultant, MPD
Deurali-Janta Pharmaceuticals Pvt. Ltd.
SLIMAGE